Anavex Life Sciences (US:AVXL) Globenewswire·2025-10-10 11:30Core Insights - Anavex Life Sciences Corp. presented advancements in Alzheimer's disease care through its oral drug candidate, blarcamesine, at the 35th Alzheimer Europe Conference [1] Company Overview - Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company focused on innovative treatments for neurodegenerative, neurodevelopmental, and neuropsychiatric disorders, including Alzheimer's disease and Parkinson's disease [3] - The lead drug candidate, ANAVEX2-73 (blarcamesine), has completed Phase 2a and Phase 2b/3 clinical trials for Alzheimer's disease and has shown potential in treating other CNS disorders [3] - The drug is designed to restore cellular homeostasis by targeting SIGMAR1 and muscarinic receptors, with preclinical studies indicating its ability to halt or reverse Alzheimer's disease progression [3] Clinical Development - ANAVEX2-73 has demonstrated various properties such as anticonvulsant, anti-amnesic, neuroprotective, and anti-depressant effects in animal models, suggesting its potential for broader CNS applications [3] - The company has received funding from the Michael J. Fox Foundation for research on ANAVEX2-73 in Parkinson's disease [3] - Another candidate, ANAVEX3-71, is in clinical stages and shows promise in addressing major Alzheimer's disease hallmarks, including cognitive deficits and amyloid and tau pathologies [3]